Search Result

Results for "

SSTR2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD3 (1) Dopamine Receptor (1) Small Interfering RNA (siRNA) (3) Somatostatin Receptor (13)
By Research Areas:	Cancer (11) Endocrinology (2) Metabolic Disease (1) Neurological Disease (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS13823

SSTR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SSTR2 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSTR2 Human Pre-designed siRNA Set A SSTR2 Human Pre-designed siRNA Set A

HY-RS13824

Sstr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Sstr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr2 Mouse Pre-designed siRNA Set A Sstr2 Mouse Pre-designed siRNA Set A

HY-RS13825

Sstr2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Sstr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr2 Rat Pre-designed siRNA Set A Sstr2 Rat Pre-designed siRNA Set A

HY-163317

MMC(TMZ)-TOC	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC targets delivery of TMZ to SSTR2-positive tumor cells .

HY-P3124

BIM-23190	Somatostatin Receptor	Cancer
BIM-23190, a somatostatin analog, a selective *SSTR2* and *SSTR5* agonist, exhibits K_i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .

HY-P2545

[Tyr1]-Somatostatin-14

Somatostatin Receptor Endocrinology

[Tyr1]-Somatostatin-14 could binds to SSTR2 .

[Tyr1]-Somatostatin-14	Somatostatin Receptor	Endocrinology
[Tyr1]-Somatostatin-14 could binds to *SSTR2* .

HY-P10137

Satoreotide JR11	Somatostatin Receptor	Cancer
Satoreotide (JR11) is a *SSTR2* antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing .

HY-P2434

AP102	Somatostatin Receptor	Neurological Disease Metabolic Disease Cancer
AP102 is a dual *SSTR2/SSTR5*-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to *SSTR2* and *SSTR5* (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research .

HY-P5362

NODAGA-LM3	Somatostatin Receptor	Cancer
NODAGA-LM3 can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 is a *SSTR2* antagonist, and can be used for imaging of SSTR positive paragangliomas ^[2].

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors ^[2].

HY-P5362A

NODAGA-LM3 TFA	Somatostatin Receptor	Cancer
NODAGA-LM3 TFA can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 TFA is a *SSTR2* antagonist, and can be used for imaging of SSTR positive paragangliomas ^[2].

HY-P3124A

BIM-23190 hydrochloride	Somatostatin Receptor	Cancer
BIM-23190 hydrochloride, a somatostatin analog, a selective *SSRT2* and SSRT5 agonist, exhibits K_i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting *SSTR2* binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P4555

(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide	Somatostatin Receptor	Neurological Disease
(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide (Compound 4) is a somatostatin analog with K_ds of 0.61, 11.05, 23.5, 1200 and >1000 nM for *SSTR5, SSTR3, SSTR2, SSTR1* and *SSTR4*, respectively .

HY-P3618

Cortistatin 29	Somatostatin Receptor	Neurological Disease
Cortistatin 29 is a neuropeptide. Cortistatin 29 alleviates neuropathic pain. Cortistatin 29 binds with high affinity all somatostatin (SS) receptor subtypes and shows IC₅₀ values of 2.8, 7.1, 0.2, 3.0, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin 29 shows anti-fibrotic effects ^[2] .

HY-P0024

Veldoreotide DG3173; PTR-3173
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the *somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH)* secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-P0024A

Veldoreotide TFA DG3173 TFA; PTR-3173 TFA	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the *somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH)* secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

Cat. No.	Product Name	Target	Research Area